PT  - JOURNAL ARTICLE
AU  - Yellapu, Gayatri Devi
AU  - Rudraraju, Gowrisree
AU  - Sripada, Narayana Rao
AU  - Mamidgi, Baswaraj
AU  - Jalukuru, Charan
AU  - Firmal, Priyanka
AU  - Yechuri, Venkat
AU  - Varanasi, Sowmya
AU  - Peddireddi, Venkata Sudhakar
AU  - Bhimarasetty, Devi Madhavi
AU  - Kanisetti, Sidharth
AU  - Joshi, Niranjan
AU  - Mohapatra, Prasant
AU  - Pamarthi, kiran
TI  - Development and Clinical Validation of Swaasa AI Platform for screening and prioritization of Pulmonary TB
AID  - 10.1101/2022.09.19.22280114
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.09.19.22280114
4099  - http://medrxiv.org/content/early/2023/02/22/2022.09.19.22280114.short
4100  - http://medrxiv.org/content/early/2023/02/22/2022.09.19.22280114.full
AB  - Acoustic signal analysis has been employed in various medical devices. However, studies involving cough sound analysis to screen the potential Pulmonary Tuberculosis (PTB) suspects are very few. The main objective of this cross-sectional validation study was to develop and validate the Swaasa AI platform to screen and prioritize at risk patients for PTB based on the signature cough sound as well as symptomatic information provided by the subjects. The voluntary cough sound data was collected at Andhra Medical College-India. An Algorithm based on multimodal Convolutional Neural Network (CNN) architecture and Feedforward Artificial Neural Network (FFANN) (tabular features) was built and validated on a total of 567 subjects, comprising 278 positive and 289 negative PTB cases. The output from these two models was combined to detect the likely presence (positive cases) of PTB. In the clinical validation phase, the AI-model was found to be 86.82% accurate in detecting the likely presence of PTB with 90.36% sensitivity and 84.67% specificity. The pilot testing of model was conducted at a peripheral health care centre, RHC Simhachalam-India on 65 presumptive PTB cases. Out of which, 15 subjects truly turned out to be PTB positive with a Positive Predictive Value of 75%. The validation results obtained from the model are quite encouraging. This platform has the potential to fulfil the unmet need of a cost-effective PTB screening method. It works remotely, presents instantaneous results, and does not require a highly trained operator. Therefore, it could be implemented in various inaccessible, resource-poor parts of the world.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2021/09/036609Clinical Protocols http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=60601&EncHid=&userName=Swaasa%20Artificial%20Intelligence%20Platform%20for%20detecting%20likely%20presence%20of%20Pulmonary%20Tuberculosis Funding StatementThis study is supported by the UK Government (British High Commission, New Delhi). This is a commissioned research report on commercial terms between C-CAMP and the UK Government (British High Commission, New Delhi).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The methods were performed in accordance with relevant guidelines and regulations and approved by Andhra Medical college (AMC)- Institutional Ethics Committee (IEC).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors